X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
index medicus (18) 18
mela7 (18) 18
oncology (17) 17
middle aged (16) 16
female (15) 15
male (15) 15
original reports (14) 14
adult (12) 12
aged (11) 11
to6 (9) 9
melanoma - drug therapy (8) 8
melanoma - pathology (8) 8
metastatic melanoma (8) 8
skin neoplasms - pathology (8) 8
melanoma - mortality (6) 6
to21 (6) 6
aged, 80 and over (5) 5
mela5 (5) 5
melanoma - immunology (5) 5
melanoma - therapy (5) 5
prognosis (5) 5
skin neoplasms - drug therapy (5) 5
treatment outcome (5) 5
antibodies, monoclonal - adverse effects (4) 4
antibodies, monoclonal - therapeutic use (4) 4
disease-free survival (4) 4
immunotherapy (4) 4
ipilimumab (4) 4
kaplan-meier estimate (4) 4
mela6 (4) 4
melanoma - genetics (4) 4
melanoma - secondary (4) 4
skin neoplasms - mortality (4) 4
survival rate (4) 4
young adult (4) 4
antineoplastic agents - therapeutic use (3) 3
cancer (3) 3
drug administration schedule (3) 3
expression (3) 3
lymphocytes, tumor-infiltrating - immunology (3) 3
melanoma - blood (3) 3
neoplasm metastasis (3) 3
neoplasm staging (3) 3
protein kinase inhibitors - therapeutic use (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
skin neoplasms - genetics (3) 3
therapy (3) 3
adolescent (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibody (2) 2
antitumor-activity (2) 2
blockade (2) 2
carcinoma (2) 2
cd4-positive t-lymphocytes - drug effects (2) 2
cd4-positive t-lymphocytes - immunology (2) 2
cd8-positive t-lymphocytes - drug effects (2) 2
cd8-positive t-lymphocytes - immunology (2) 2
diagnosis in oncology (2) 2
dose-response relationship, drug (2) 2
efficacy (2) 2
fever - chemically induced (2) 2
improved survival (2) 2
interleukin-2 (2) 2
mela1 (2) 2
mela2 (2) 2
melanoma (2) 2
multivariate analysis (2) 2
mutation - genetics (2) 2
neutropenia - chemically induced (2) 2
pathway (2) 2
phase-ii trial (2) 2
progression (2) 2
prospective studies (2) 2
prostate-cancer (2) 2
proto-oncogene proteins b-raf - antagonists & inhibitors (2) 2
recombinant proteins - administration & dosage (2) 2
skin neoplasms - immunology (2) 2
skin neoplasms - therapy (2) 2
survival analysis (2) 2
t-cells (2) 2
to11 (2) 2
to8 (2) 2
vemurafenib (2) 2
acquired-resistance (1) 1
actinic keratosis (1) 1
activate (1) 1
activating transcription factor 2 - analysis (1) 1
adjuvants, immunologic - adverse effects (1) 1
adjuvants, immunologic - therapeutic use (1) 1
administration, oral (1) 1
adoptive immunotherapy (1) 1
adverse events (1) 1
algorithms (1) 1
alopecia - chemically induced (1) 1
american-joint-committee (1) 1
amplification (1) 1
anti-pd-1 (1) 1
anti-pd-1 antibody (1) 1
antigen (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1020 - 1030
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 7, pp. 917 - 924
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 1, pp. 74 - 82
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 26, pp. 3182 - 3190
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2012, Volume 30, Issue 3, pp. 316 - 321
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2152 - 2159
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2924 - 2932
Purpose This multicenter randomized trial was designed to test whether melanoma-associated helper peptides augment CD8(+) T-cell responses to a melanoma... 
METASTATIC MELANOMA | PHASE-II TRIAL | T-CELL RESPONSES | MEDIATED-IMMUNITY | CANCER-PATIENTS | COLONY-STIMULATING FACTOR | ONCOLOGY | FACILITATED ADOPTIVE IMMUNOTHERAPY | LOW-DOSE CYCLOPHOSPHAMIDE | ANTITUMOR IMMUNE-RESPONSE | CLINICAL-OUTCOMES | United States | Humans | Middle Aged | Male | Interferon-gamma - metabolism | Melanoma-Specific Antigens - therapeutic use | Cyclophosphamide - adverse effects | Melanoma-Specific Antigens - adverse effects | Cyclophosphamide - therapeutic use | Adjuvants, Immunologic - adverse effects | CD4-Positive T-Lymphocytes - immunology | Cancer Vaccines - therapeutic use | Time Factors | Skin Neoplasms - mortality | Tetanus Toxin - immunology | Female | Adjuvants, Immunologic - therapeutic use | Melanoma-Specific Antigens - immunology | Skin Neoplasms - pathology | Enzyme-Linked Immunosorbent Assay | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Peptides - immunology | Kaplan-Meier Estimate | Cancer Vaccines - adverse effects | Survival Rate | Treatment Outcome | Melanoma - pathology | Tetanus Toxin - therapeutic use | Disease-Free Survival | Melanoma - immunology | CD8-Positive T-Lymphocytes - drug effects | CD8-Positive T-Lymphocytes - immunology | Melanoma - therapy | Neoplasm Staging | CD4-Positive T-Lymphocytes - drug effects | Peptides - adverse effects | Peptides - therapeutic use | Melanoma - mortality | Index Medicus | Original Reports | To6 | To21 | Mela7
Journal Article